Mirador Capital Partners LP Grows Stake in LifeMD, Inc. (NASDAQ:LFMD)

Mirador Capital Partners LP increased its stake in LifeMD, Inc. (NASDAQ:LFMD) by 139.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 106,059 shares of the company’s stock after purchasing an additional 61,731 shares during the quarter. Mirador Capital Partners LP owned approximately 0.24% of LifeMD worth $525,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. JPMorgan Chase & Co. raised its stake in LifeMD by 496.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 88,173 shares of the company’s stock valued at $462,000 after acquiring an additional 73,389 shares during the period. Barclays PLC lifted its position in shares of LifeMD by 311.7% during the third quarter. Barclays PLC now owns 49,017 shares of the company’s stock worth $257,000 after acquiring an additional 37,112 shares in the last quarter. Geode Capital Management LLC lifted its holdings in LifeMD by 11.4% during the 3rd quarter. Geode Capital Management LLC now owns 819,233 shares of the company’s stock worth $4,293,000 after purchasing an additional 83,598 shares in the last quarter. XTX Topco Ltd boosted its stake in LifeMD by 306.8% in the 3rd quarter. XTX Topco Ltd now owns 55,738 shares of the company’s stock worth $292,000 after purchasing an additional 42,037 shares during the period. Finally, State Street Corp grew its stake in LifeMD by 20.0% during the third quarter. State Street Corp now owns 1,155,495 shares of the company’s stock valued at $6,055,000 after acquiring an additional 192,861 shares in the last quarter. 35.52% of the stock is owned by institutional investors.

LifeMD Stock Up 0.2 %

LifeMD stock opened at $4.91 on Thursday. The business has a 50-day simple moving average of $5.62 and a two-hundred day simple moving average of $5.49. The company has a market cap of $212.65 million, a P/E ratio of -7.67 and a beta of 1.49. LifeMD, Inc. has a 52-week low of $3.99 and a 52-week high of $12.88.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 price objective on shares of LifeMD in a report on Friday, September 20th. KeyCorp reduced their price target on shares of LifeMD from $10.00 to $7.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Mizuho started coverage on shares of LifeMD in a research report on Wednesday, December 4th. They set a “neutral” rating and a $7.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of LifeMD in a research note on Monday, November 11th. Finally, Lake Street Capital initiated coverage on LifeMD in a research note on Tuesday, December 10th. They issued a “buy” rating and a $12.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $11.14.

Insiders Place Their Bets

In related news, CEO Justin Schreiber sold 25,000 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $5.19, for a total value of $129,750.00. Following the completion of the transaction, the chief executive officer now owns 2,703,715 shares of the company’s stock, valued at approximately $14,032,280.85. This trade represents a 0.92 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 15.97% of the stock is currently owned by company insiders.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.